

49TH ANNUAL MACULA SOCIETY MEETING

February 25-28, 2026

Coronado, California



Wednesday, February 25, 2026

1:07 – 2:03pm Session: Case Conference I

Moderator: **Jose S. Pulido, MD, MS, MPH, MBA**

1:49 p.m. ***Verde que te quiero verde***

Jose S. Pulido, MD, MS, MPH, MBA, Sidra Zafar, Tatyana Milman

Thursday, February 26, 2026

7:00 – 7:45am Session: DIABETIC RETINOPATHY II

7:40 a.m. ***Retinal Fluid, Thickness Fluctuations, and Vascular Leakage in Study Eyes Treated with Port Delivery Platform with Ranibizumab vs Fellow Eyes Treated with Anti-VEGF Injections in Patients With Bilateral Diabetic Macular Edema in the Pagoda Trial***

Jason Hsu, MD, David Eichenbaum, Jordan M. Graff, MD, FACS, Yi-Ting Hsieh, Patricia Udaondo, Robert S. Wirthlin, Shamika Gune, Dominic Heinrich, Melissa Kaye Jones, Amy Lin

7:40 – 8:55am SESSION: NV AMD I: CLINICAL TRIALS

Moderator: **Carl D. Regillo, MD**

7:55 a.m. ***Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD): Long-Term Results from the OPTIC Trial***

Brian C. Joondeph, MD MPS FACS, James Calder Major, MD PhD, Charles Clifton Wykoff, MD, PhD, David S. Boyer, MD, Carl D. Regillo, MD, Carl Joshua Danzig, MD, Brandon Busbee, Dante Joseph Pieramici, MD, Arshad M. Khanani, MD, MA, FASRS, Pauravi Gandhi, Kenneth Glasscock, Dina Akasheh, MBA, PhD, Joanna Do, Jennifer Danesh, Traci Elnora Clemons, PhD, Lixin Wang, MD., PhD, Adam Turpcu, Rabia Gurses Ozden, MD, Star Seyedkazemi, PharmD, PharmD

8:00 a.m. ***Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD): Phase 2 LUNA Update***

Carl D. Regillo, MD, Dante Joseph Pieramici, MD, Paul Hahn, MD, PhD, Charles Clifton Wykoff, MD, PhD, Sean Adrean, Mark Barakat, Carl Joshua Danzig, MD, Benjamin Bakall, David S. Boyer, MD, Arshad M. Khanani, MD, MA, FASRS, Veeral Sheth, MD, MBA, Bill Tan, Ashley Jo Clark, Traci Elnora Clemons, PhD, Pauravi Gandhi, Kenneth Glasscock, Dina Akasheh, MBA, PhD, Adam Turpcu, Rabia Gurses Ozden, MD, Star Seyedkazemi, PharmD, PharmD

8:55 – 10:25am SESSION: IMAGING II

Moderator: **Julia A. Haller, MD**

2:30 – 3:30pm SESSION: WOMEN IN RETINA

2:30 – 3:30pm ***Women in Retina***

Julia A. Haller, MD

Friday, February 27, 2026

8:35 – 8:40am SESSION: NV AMD II

8:35 a.m. ***Up to 7-Year Efficacy, Macular Atrophy, and Safety of the Port Delivery Platform With Ranibizumab in Patients With nAMD: Results from the Portal Extension Trial***

Dante Joseph Pieramici, MD, Carl C. Awh, MD, FASRS, Jordan M. Graff, MD, FACS, Arshad M. Khanani, MD, MA, FASRS, Robert A. Mitra, MD, **Carl D. Regillo, MD**, Shamika Gune, Sophie LePogam, PhD, Natasha Singh, Pharm D, Gian-Andrea Thanei

11:25 – 11:43am SESSION: NON NV AMD III

11:25 a.m. ***Earlier Treatment Yields Better Outcomes: 5 Years of Pegcetacoplan Treatment for Geographic Atrophy Secondary to AMD***

Dante Joseph Pieramici, MD, Carl C. Awh, MD, FASRS, Jordan M. Graff, MD, FACS, Arshad M. Khanani, MD, MA, FASRS, Robert A. Mitra, MD, **Carl D. Regillo, MD**, Shamika Gune, Sophie LePogam, PhD, Natasha Singh, Pharm D, Gian-Andrea Thanei

11:35 a.m. ***Fellow Eye Analysis, Including Ellipsoid Zone (EZ) Loss, in Bilateral GA Due to AMD: Long-Term Data from the OAKS, DERBY, and GALE Studies***

Sunir J. Garg, MD, FACS, Diana V. Do, MD, Srinivas Reddy Satta, MD, Robyn Guymer, Gregor Sebastian Reiter, BA, Jason Lin, PharmD, Kineta Naidu, Emma Foos, Song Yu, Caroline Robin Baumal, Ursula Schmidt-Erfurth, MD

-

4:13 – 4:18pm SESSION: BASIC SCIENCE

4:13 p.m. ***In Silico Analysis of MHC-I-Associated Autoimmune Responses Related to Chorioretinal Atrophy Following RPE65 Gene Therapy***

Marion Ronit Munk, MD, PhD, FEBO, FMH, **Jose S. Pulido, MD, MS, MPH, MBA**, Isil Kutluturk Karagöz

-

5:23 – 5:31pm SESSION: TUMORS

5:23 p.m. ***Retinoblastoma 2026: Agreement and Disagreement***

David H. Abramson, MD, **Carol L. Shields, MD**, Francis L. Munier, MD, Guillermo Chantada